Harnessing the potential of AI/ML to expand the horizons of the oligonucleotide therapeutics field

Artificial intelligence and machine learning (AI/ML) are already making their presence felt across the life sciences, but what can they offer the oligonucleotide therapeutics space as it battles to reach new therapeutic areas and opportunities? David McCall, Senior Editor, BioInsights, talks to Arijit Bhowmick, Director, Oligonucleotide Therapeutics, insitro, about the current state of the oligonucleotide therapeutics field, and how the powers of AI/ML can be harnessed to create better drugs, particularly oligos.

Please enter your email to access content Read now